IL152023A0 - Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same - Google Patents

Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same

Info

Publication number
IL152023A0
IL152023A0 IL15202301A IL15202301A IL152023A0 IL 152023 A0 IL152023 A0 IL 152023A0 IL 15202301 A IL15202301 A IL 15202301A IL 15202301 A IL15202301 A IL 15202301A IL 152023 A0 IL152023 A0 IL 152023A0
Authority
IL
Israel
Prior art keywords
adenosine
compounds
same
pharmaceutical compositions
defecation
Prior art date
Application number
IL15202301A
Other languages
English (en)
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of IL152023A0 publication Critical patent/IL152023A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B10/00—Transmission systems employing electromagnetic waves other than radio-waves, e.g. infrared, visible or ultraviolet light, or employing corpuscular radiation, e.g. quantum communication
    • H04B10/11—Arrangements specific to free-space transmission, i.e. transmission through air or vacuum
    • H04B10/112—Line-of-sight transmission over an extended range

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electromagnetism (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15202301A 2000-04-26 2001-04-26 Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same IL152023A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000126489 2000-04-26
JP2000220124 2000-07-21
PCT/JP2001/003643 WO2001080893A1 (fr) 2000-04-26 2001-04-26 Compositions medicinales favorisant les mouvements intestinaux

Publications (1)

Publication Number Publication Date
IL152023A0 true IL152023A0 (en) 2003-04-10

Family

ID=26590887

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15202301A IL152023A0 (en) 2000-04-26 2001-04-26 Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same
IL188052A IL188052A0 (en) 2000-04-26 2007-12-11 A defecation promoting agent having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL188052A IL188052A0 (en) 2000-04-26 2007-12-11 A defecation promoting agent having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same

Country Status (16)

Country Link
US (3) US7189717B2 (ko)
EP (2) EP1510222A3 (ko)
JP (1) JP4128360B2 (ko)
KR (2) KR20070058022A (ko)
CN (1) CN1197621C (ko)
AT (1) ATE284712T1 (ko)
AU (2) AU2001252606B2 (ko)
CA (1) CA2407013A1 (ko)
DE (1) DE60107835T2 (ko)
HU (1) HUP0300927A2 (ko)
IL (2) IL152023A0 (ko)
MX (1) MXPA02010552A (ko)
NO (1) NO20025116L (ko)
NZ (1) NZ521633A (ko)
RU (2) RU2294762C2 (ko)
WO (1) WO2001080893A1 (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070058022A (ko) 2000-04-26 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 배변을 촉진하는 의약 조성물
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (ko) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
PT2942082T (pt) 2002-01-28 2019-06-06 Kyowa Hakko Kogyo Kk Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
US20030232813A1 (en) * 2002-04-10 2003-12-18 Orchid Chemicals & Pharmaceuticals Limited Novel amino substituted pyrimidinone derivatives
ES2229928B1 (es) * 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
WO2005058883A1 (en) * 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
SE0400233D0 (sv) * 2004-02-04 2004-02-04 Ltp Lipid Technologies Provide Rektal komposition
CA2561383A1 (en) * 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Prophylactic and/or therapeutic agents for chronic musculoskeletal pain
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
DE602006020864D1 (de) * 2005-04-11 2011-05-05 Almirall Sa 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
AR053712A1 (es) * 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
FR2902010B1 (fr) * 2006-06-12 2008-08-22 Pierre Fabre Medicament Sa Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique
US20080009623A1 (en) * 2006-07-06 2008-01-10 Eisai R&D Management Co., Ltd. Pyrimidine compounds
US8227027B2 (en) * 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
EP2268641B1 (en) 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
JP5426156B2 (ja) * 2008-12-25 2014-02-26 フマキラー株式会社 排便促進用組成物
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
CN103261200B (zh) 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
EP2812324B1 (en) 2012-02-08 2021-09-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
PL3321262T3 (pl) 2012-03-01 2021-06-28 Array Biopharma, Inc. Inhibitory kinaz serynowo/treoninowych
AR092253A1 (es) 2012-08-27 2015-04-08 Array Biopharma Inc Inhibidores de serina/treonina cinasa
ES2580702B1 (es) * 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
JP2017149663A (ja) * 2016-02-24 2017-08-31 株式会社Ｌｔｔバイオファーマ 過敏性腸症候群治療剤
CN105687225B (zh) * 2016-02-26 2018-07-06 四川好医生攀西药业有限责任公司 一种治疗肠易激综合征的药物组合物及其制备方法和应用
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
WO2019121374A1 (en) * 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
CN112423758A (zh) * 2018-07-10 2021-02-26 尼康治疗公司 腺苷受体结合化合物
US20210395225A1 (en) * 2018-10-24 2021-12-23 Leadxpro Ag Functionalized aminotriazines
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
US4673680A (en) * 1985-09-18 1987-06-16 Pendleton Robert G α2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility
JPH06102662B2 (ja) 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
JPH04271770A (ja) * 1991-02-27 1992-09-28 Asahi:Kk お茶
JP3343965B2 (ja) * 1992-10-31 2002-11-11 ソニー株式会社 音声符号化方法及び復号化方法
CN1088053A (zh) * 1993-01-04 1994-06-22 谷中村 一种益寿保健茶叶
JPH06211669A (ja) 1993-01-14 1994-08-02 Kyowa Hakko Kogyo Co Ltd 腸運動の異常亢進治療剤
WO1994016702A1 (en) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
JP3123286B2 (ja) * 1993-02-18 2001-01-09 ソニー株式会社 ディジタル信号処理装置又は方法、及び記録媒体
GB9309573D0 (en) * 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
JP3277679B2 (ja) * 1994-04-15 2002-04-22 ソニー株式会社 高能率符号化方法と高能率符号化装置及び高能率復号化方法と高能率復号化装置
JP2000506532A (ja) 1996-03-13 2000-05-30 スミスクライン・ビーチャム・コーポレイション サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
JP2002514196A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジノンおよびピリドン化合物ならびに使用方法
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
CA2315736A1 (en) * 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
JP3990061B2 (ja) 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
CA2239294A1 (en) * 1998-05-29 1999-11-29 Majid Foodeei Methods and apparatus for efficient quantization of gain parameters in glpas speech coders
PL204628B1 (pl) * 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
AU4506399A (en) * 1998-06-05 1999-12-30 Novartis Ag Aryl pyridinyl thiazoles
DE69910213T2 (de) 1998-06-23 2004-07-01 Glaxo Group Ltd., Greenford 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
FR2791167B1 (fr) * 1999-03-17 2003-01-10 Matra Nortel Communications Procedes de codage, de decodage et de transcodage audio
KR100694684B1 (ko) 1999-07-02 2007-03-13 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 이미다졸 화합물 및 당뇨병 치료약
EP1136486A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
AU2001248365A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
KR20070058022A (ko) 2000-04-26 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 배변을 촉진하는 의약 조성물

Also Published As

Publication number Publication date
EP1510222A2 (en) 2005-03-02
US20070054876A1 (en) 2007-03-08
US7189717B2 (en) 2007-03-13
AU2001252606B2 (en) 2005-07-07
AU5260601A (en) 2001-11-07
EP1283056B1 (en) 2004-12-15
MXPA02010552A (es) 2003-03-10
EP1283056A1 (en) 2003-02-12
IL188052A0 (en) 2008-03-20
JP4128360B2 (ja) 2008-07-30
ATE284712T1 (de) 2005-01-15
US20030171383A1 (en) 2003-09-11
CN1197621C (zh) 2005-04-20
RU2005127415A (ru) 2007-03-10
CA2407013A1 (en) 2002-10-22
KR20070058022A (ko) 2007-06-07
DE60107835T2 (de) 2005-12-22
NO20025116L (no) 2002-12-23
US20060270674A1 (en) 2006-11-30
CN1426310A (zh) 2003-06-25
NZ521633A (en) 2005-01-28
NO20025116D0 (no) 2002-10-24
WO2001080893A1 (fr) 2001-11-01
KR20020089495A (ko) 2002-11-29
DE60107835D1 (de) 2005-01-20
KR100782091B1 (ko) 2007-12-04
EP1510222A3 (en) 2007-05-23
RU2002131637A (ru) 2004-03-27
RU2294762C2 (ru) 2007-03-10
EP1283056A4 (en) 2003-07-02
HUP0300927A2 (hu) 2003-07-28

Similar Documents

Publication Publication Date Title
IL152023A0 (en) Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same
EP1658858A3 (en) Use of botulinum toxin for the treatment of unstable bladder
US5266573A (en) Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
AU3254395A (en) Use of a combination product that contains a competitive progesterone antagonist and a gestagen for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri
HUP9700992A3 (en) 3-(piperid-4-yl)1,2-benzisoxazole and 3-(piperazin-4-yl)-1,2-benzisoxazole compounds, process for their preparation and pharmaceutical compositions containing them
HK1022439A1 (en) Pharmaceutical compositions containing lactobacilli for treatment fo vaginal infections
CA2396159A1 (en) Novel substituted benzimidazole dosage forms and method of using same
CA2321523A1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
HU9603228D0 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
RS47304A (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
EP2767291A3 (en) Treatment of glycogen storage disease type II
ATE534656T1 (de) Neue oligosaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
IE63470B1 (en) Use of sertraline for the treatment of premature ejaculation
WO2002034716A3 (en) Pyrrolidine modulators of ccr5 chemokine receptor activity
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
HUP0302538A3 (en) 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
HUP0203429A3 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone, process for their preparation and pharmaceutical compositions containing them
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
BR9909971A (pt) Uso de um composto, processo para tratamento ou prevenção da sìndrome de intestinos irritáveis, e, composição farmacêutica para o tratamento da sìndrome dos intestinos irritáveis
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
IL95472A (en) A medicinal product containing sertraline for use in the treatment of chemical addictions
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
BR9507848A (pt) Composição farmcéutica contendo espiramicina eventualmente em associação com o metronizadol
HU0100122D0 (en) Use of tiludronic acid and derivatives thereof in poultry for preparation of a medicinal product for preventing and treating osteoporosis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees